CD8A and non-small cell lung carcinoma: A study evaluating peripheral blood samples of NSCLC patients treated with anti-PD-1 by conventional flow cytometry demonstrated that early expansion of peripheral PD-1+ CD8 T cells was associated with clinical efficacy (59).